TrialClinical pharmacokinetics2019

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.

Ahmed A Suleiman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.